Artivion (AORT) to Release Quarterly Earnings on Monday

Artivion (NYSE:AORT) will likely be posting its Q1 2025 quarterly earnings results after the market closes on Monday, May 5th. Analysts expect the company to announce earnings of $0.12 per share and revenue of $94.81 million for the quarter. Artivion has set its FY 2025 guidance at EPS.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The firm had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Price Performance

Shares of NYSE:AORT opened at $23.36 on Friday. The company has a market cap of $997.22 million, a P/E ratio of -1,168.00 and a beta of 1.65. The company has a 50-day moving average price of $23.95 and a 200 day moving average price of $27.20. Artivion has a 52 week low of $20.64 and a 52 week high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Insiders Place Their Bets

In other news, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $1,151,280.36. Following the transaction, the chief executive officer now directly owns 663,882 shares of the company’s stock, valued at $18,130,617.42. The trade was a 5.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Jean F. Holloway sold 5,335 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares in the company, valued at $4,091,010.69. The trade was a 3.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,799 shares of company stock valued at $2,356,223 in the last quarter. 7.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on AORT. Stifel Nicolaus lowered their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Needham & Company LLC decreased their price target on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.